When should I call a doctor about heart palpitations on glp-1 medications?

Resting heart rate consistently >100 bpm; Palpitations + chest pain, shortness of breath, or fainting (call 911); Irregularly irregular rhythm felt at the pulse (possible atrial fibrillation); New or worsening palpitations after starting any new medication

How common is heart palpitations on glp-1 medications on GLP-1?

Common (mild rate increase) — 15-20% report awareness

Heart palpitations on GLP-1 medications — Management, Causes, When to Call Doctor

Key takeaways

• Frequency: Common (mild rate increase) — 15-20% report awareness.
• Trial reference: SUSTAIN-6 / SELECT (semaglutide CV outcomes) (15-20% awareness).
• Management: typically resolves within 4-8 weeks as the body adapts.
• When to call doctor: see red-flag list below.

Why this happens

GLP-1 receptor activation has direct cardiac effects, raising resting heart rate by ~3-7 bpm on average. The mechanism is incompletely understood but appears mediated by sympathetic activation. In most patients this is asymptomatic; some perceive it as fluttering or skipped beats.

How to manage it

Track resting heart rate at home — note baseline before starting, recheck after each dose increase
Limit caffeine — it compounds the effect
Avoid stimulants (decongestants, pre-workout supplements) during titration
Stay well-hydrated — dehydration worsens palpitation perception
Regular cardio exercise improves vagal tone and dampens awareness
Sleep adequately — sleep debt elevates resting heart rate

GLP1Zoom doesn't prescribe — these are general management guidance from FDA labels and clinical trial reports. Personalized recommendations require your prescribing clinician.

When to call your doctor

Red flags — seek medical attention

• Resting heart rate consistently >100 bpm
• Palpitations + chest pain, shortness of breath, or fainting (call 911)
• Irregularly irregular rhythm felt at the pulse (possible atrial fibrillation)
• New or worsening palpitations after starting any new medication

Drug-specific notes

All GLP-1s: FDA labels acknowledge ~3-7 bpm resting heart rate increase; cardiovascular outcomes net positive in LEADER/SUSTAIN trials
Wegovy: SUSTAIN-6 + SELECT trials show net cardiovascular benefit despite rate increase

Other GLP-1 symptoms

Symptom management is general guidance based on FDA-approved prescribing information. Always discuss specifics with your prescribing clinician. In medical emergencies, call 911 or go to the nearest emergency department. Full disclaimer.

References